<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106325</url>
  </required_header>
  <id_info>
    <org_study_id>13-00794</org_study_id>
    <nct_id>NCT02106325</nct_id>
  </id_info>
  <brief_title>Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients</brief_title>
  <official_title>A Randomized, Double-Blinded Controlled Trial of an N-Methyl D-Aspartate Antagonist as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment
      for people with Major Depressive Disorder. This study plans to explore the potential that
      Ketamine's rapid antidepressant action holds for improving outcomes in patients presenting to
      the Emergency Department with severe depression. Since this is a controlled trial we will use
      an IV of Ketamine or and equivalent volume of Diphenhydramine. Subjects will be randomly
      assigned to receive Ketamine or Benadryl. Investigators will then compare measures of mood
      pre- and post-infusion in the Emergency Department. To supplement self-reported measures of
      depressive symptoms(e.g. mood), investigators will obtain objective measures of the
      biological aspects of Major Depressive Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the use of ketamine as a potential rapidly-acting antidepressant (RAA) for
      Emergency Department (ED) patients with major depressive disorder (MDD).

      Investigators will conduct a randomized controlled study to evaluate the rapidity and
      persistence of antidepressant effects of a single sub-anesthetic dose of intravenous (IV)
      ketamine (0.25mg/kg) or an equivalent volume of diphenhydramine (25mg) delivered IV over 1-2
      minutes, by comparing measures of mood pre- and post-infusion in Emergency Department (ED)
      patients with MDD. Subjects will be randomly assigned (1:1) to receive a bolus of ketamine or
      diphenhydramine. To supplement self-reported measures of depressive symptoms (e.g., mood,
      suicidal ideation, etc.), investigators will obtain objective measures of heart rate and
      heart rate variability, measure serum levels of the pro- and anti-inflammatory cytokines
      (interleukin IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, and tissue necrosis factor, TNF-α), which
      have been shown to play an important role in stress, depression and suicidal behavior. In
      addition, investigators will obtain serum levels of brain derived neurotrophic factor (BDNF)
      because reduced serum BDNF has been described during acute depressive episodes in patients
      with MDD, with reports of rescue effects following treatment with various antidepressants and
      with ketamine (Aydemir 2005, Gervasoni 2005, Karege 2002, Karege 2005, Duncan 2013, Shimizu
      2003). Investigators will also measure serum magnesium levels, as these have been shown to
      correlate in a predictive manner with response to conventional antidepressants (Camardese
      2012), and there are data to suggest that ketamine's efficacy in treatment-resistant
      depression could be related to a relative magnesium deficiency in such patients (Murck 2013).

      This study will allow investigators to determine to what extent low-dose ketamine, an
      N-Methyl-D-Aspartate (NMDA) antagonist, achieves a rapid reduction in symptoms for severely
      depressed ED patients with or without suicidal ideation. For decades, much higher doses of IV
      ketamine (1-2mg/kg) have been used routinely in the ED as a dissociative anesthetic (Green
      2011). In 2011, an open-label study was the first published of the use of low dose ketamine
      (0.2mg/kg), administered by rapid intravenous infusion, in the ED setting for acutely
      depressed patients which demonstrated its feasibility, safety, preliminary efficacy and
      acceptability to both ED patients and staff (Larkin 2011). One long-term goal of this
      research is to expand treatment options available to depressed ED patients that mitigate the
      need for inpatient admission and serve as a safety bridge to future out-patient treatment for
      major depression. As an adjunct to standard treatment, low-dose NMDA receptor antagonists
      have the potential to positively impact: ED waiting times; repeat visits to the ED;
      short-term risk of suicide attempts; length of stay on inpatient units and the need for
      hospital admissions for many acutely depressed patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>40 Minutes Post Infusion, The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 54 points.
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>120 min post-infusion</time_frame>
    <description>BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
0-13 Indicates minimal depression 14-19 Indicates mild depression 20-28 Indicates Moderate depression 29-63 Indicates Severe depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Scale (Ham-D)</measure>
    <time_frame>4-6 hours post-infusion</time_frame>
    <description>Although the HAM-D form lists 21 items, the scoring is based on the first 17. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.
Sum the scores from the first 17 items 0-7= Normal 8-13= Mild Depression 14-18= Moderate Depression 19-22= Severe Depression &gt;23= Very Severe Depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Treatment Alliance Score</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>The I-TAS is a 10-item, Likert-style rating scale designed to assess a patient's composite treatment alliance as it develops across multi-disciplinary treatment components. The I-TAS was intended to measure the primary alliance factors identified by Hatcher and Barends (1996) of bond, goals and collaboration. Each question is scored on a scale of 0 (Completely False) to 6 (Completely True). Total scores on the ITAS range from 0 to 60, with higher scores representing greater alliance with the treatment team (better outcome). The reported score is an average of each participant's total score on the ITAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Scale for Suicidal Ideation (BSSI)</measure>
    <time_frame>40 minutes post-infusion</time_frame>
    <description>BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
0-13 Indicates minimal depression 14-19 Indicates mild depression 20-28 Indicates Moderate depression 29-63 Indicates Severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale Suicide Ideation Item (MADRS-SI)</measure>
    <time_frame>40 minutes post-infusion</time_frame>
    <description>40 Minutes Post Infusion, The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 54 points.
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Inpatient Stay</measure>
    <time_frame>2 Weeks Post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Follow-up Compliance</measure>
    <time_frame>1 Day</time_frame>
    <description>Scoring System: 0= not compliant, 1=compliant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Treatment Alliance Scale (ITAS)</measure>
    <time_frame>7 days post-infusion</time_frame>
    <description>The I-TAS is a 10-item, Likert-style rating scale designed to assess a patient's composite treatment alliance as it develops across multi-disciplinary treatment components. The I-TAS was intended to measure the primary alliance factors identified by Hatcher and Barends (1996) of bond, goals and collaboration. Each question is scored on a scale of 0 (Completely False) to 6 (Completely True). Total scores on the ITAS range from 0 to 60, with higher scores representing greater alliance with the treatment team (better outcome). The reported score is an average of each participant's total score on the ITAS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Ketamine .25mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25mg Diphenhydramine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>IV of Ketamine (.25mg/kg)</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Other names for ketamine: ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <other_name>Other names for diphenhydramine: benadryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable as determined by the medical physician

          -  Meets criteria for Major Depressive Disorder (MDD) based on a structured clinical
             Interview (MINI International Neuropsychiatric Interview).

          -  Reports symptoms of severe depression at the time of presentation, defined as a score
             of 24 or greater on the MADRS.

          -  Patients for whom a psychiatric evaluation and disposition decision has been made by
             emergency psychiatry staff to admit to an inpatient psychiatric unit at Bellevue
             Hospital Center or NYU Tisch Hospital.

          -  Each subject must have a level of understanding sufficient to sign an informed consent
             stating that the treatment being offered is not FDA approved for the treatment of
             depression and is being provided as an off-label option.

        Exclusion Criteria:

          -  Pregnancy

          -  Inability to read or understand English

          -  Current clinical signs of intoxication or delirium at time of study intervention

          -  Overdose, within previous 24 hours, of any agent which would impair ketamine
             metabolism

          -  Lifetime misuse/abuse of ketamine, phencyclidine (PCP),or related substances

          -  Lifetime history of psychotic spectrum illness

          -  First-degree relative with history of psychotic illness

          -  Lifetime diagnosis of borderline personality disorder, or as confirmed by assessment
             using items #90-104 of the SCID-II (for DSM-IV).

          -  Subjects with clinically significant abnormal findings as determined by medical
             history, physical examination, vital signs (blood pressure, heart rate, and
             respiration rate), O2 saturation measure, 12-lead ECG, clinical laboratory tests (CBC,
             chemistry panel, thyroid function tests), urine drug screen, and urine pregnancy test
             (for females of childbearing potential only).

          -  Clinically unstable medical, surgical or neurological conditions at ED presentation

          -  History of stroke or intracranial hypertension

          -  History of glaucoma

          -  Subjects with one or more seizures without a clear and resolved etiology

          -  Current NMDA antagonist medications (eg. Amantadine, Rimantadine, Lamotrigine,
             Memantine, Dextromethorphan)

          -  Known hypersensitivity to ketamine or amantadine

          -  Anti-psychotic medications (Typicals or Atypicals), with the exception of low-dose
             quetiapine (total daily dose of 100mg or less).

          -  Actively trying to commit suicide, even in a hospital setting

          -  Current homicide risk

          -  Unable or unwilling to give informed consent according to HIC guidelines

          -  Unable or unwilling to provide 2 contact phone numbers or be followed up per study
             protocol.

          -  Previous enrollment in this study.

          -  Concurrent enrollment in a research protocol investigating experimental pharmacologic
             treatments for depression at this or any other institution.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K. Casey Paleos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York Unversity School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center/Tisch Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <results_first_submitted>June 19, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Ketlar</keyword>
  <keyword>Depression</keyword>
  <keyword>Antidepressants</keyword>
  <keyword>Treatment</keyword>
  <keyword>Acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
        </group>
        <group group_id="P2">
          <title>Diphenhydramine</title>
          <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
        </group>
        <group group_id="B2">
          <title>Diphenhydramine</title>
          <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="22" upper_limit="57"/>
                    <measurement group_id="B2" value="31" lower_limit="22" upper_limit="48"/>
                    <measurement group_id="B3" value="38" lower_limit="22" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale</title>
        <description>40 Minutes Post Infusion, The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 54 points.
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale</title>
          <description>40 Minutes Post Infusion, The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 54 points.
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.82" spread="2.95"/>
                    <measurement group_id="O2" value="25.20" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beck Depression Inventory-II (BDI-II)</title>
        <description>BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
0-13 Indicates minimal depression 14-19 Indicates mild depression 20-28 Indicates Moderate depression 29-63 Indicates Severe depression</description>
        <time_frame>120 min post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory-II (BDI-II)</title>
          <description>BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
0-13 Indicates minimal depression 14-19 Indicates mild depression 20-28 Indicates Moderate depression 29-63 Indicates Severe depression</description>
          <units>Scored units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="3.94"/>
                    <measurement group_id="O2" value="24.72" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Scale (Ham-D)</title>
        <description>Although the HAM-D form lists 21 items, the scoring is based on the first 17. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.
Sum the scores from the first 17 items 0-7= Normal 8-13= Mild Depression 14-18= Moderate Depression 19-22= Severe Depression &gt;23= Very Severe Depression</description>
        <time_frame>4-6 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Scale (Ham-D)</title>
          <description>Although the HAM-D form lists 21 items, the scoring is based on the first 17. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.
Sum the scores from the first 17 items 0-7= Normal 8-13= Mild Depression 14-18= Moderate Depression 19-22= Severe Depression &gt;23= Very Severe Depression</description>
          <units>Scored units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.48" spread="2.08"/>
                    <measurement group_id="O2" value="17.00" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Treatment Alliance Score</title>
        <description>The I-TAS is a 10-item, Likert-style rating scale designed to assess a patient's composite treatment alliance as it develops across multi-disciplinary treatment components. The I-TAS was intended to measure the primary alliance factors identified by Hatcher and Barends (1996) of bond, goals and collaboration. Each question is scored on a scale of 0 (Completely False) to 6 (Completely True). Total scores on the ITAS range from 0 to 60, with higher scores representing greater alliance with the treatment team (better outcome). The reported score is an average of each participant's total score on the ITAS.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Treatment Alliance Score</title>
          <description>The I-TAS is a 10-item, Likert-style rating scale designed to assess a patient's composite treatment alliance as it develops across multi-disciplinary treatment components. The I-TAS was intended to measure the primary alliance factors identified by Hatcher and Barends (1996) of bond, goals and collaboration. Each question is scored on a scale of 0 (Completely False) to 6 (Completely True). Total scores on the ITAS range from 0 to 60, with higher scores representing greater alliance with the treatment team (better outcome). The reported score is an average of each participant's total score on the ITAS.</description>
          <units>Scored units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.52" spread="3.69"/>
                    <measurement group_id="O2" value="53.15" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Scale for Suicidal Ideation (BSSI)</title>
        <description>BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
0-13 Indicates minimal depression 14-19 Indicates mild depression 20-28 Indicates Moderate depression 29-63 Indicates Severe depression</description>
        <time_frame>40 minutes post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Scale for Suicidal Ideation (BSSI)</title>
          <description>BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.
0-13 Indicates minimal depression 14-19 Indicates mild depression 20-28 Indicates Moderate depression 29-63 Indicates Severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.40"/>
                    <measurement group_id="O2" value="1.08" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Åsberg Depression Rating Scale Suicide Ideation Item (MADRS-SI)</title>
        <description>40 Minutes Post Infusion, The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 54 points.
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
        <time_frame>40 minutes post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Åsberg Depression Rating Scale Suicide Ideation Item (MADRS-SI)</title>
          <description>40 Minutes Post Infusion, The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 54 points.
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression &gt;34 - severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.46"/>
                    <measurement group_id="O2" value="0.75" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Inpatient Stay</title>
        <time_frame>2 Weeks Post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Inpatient Stay</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="1.32"/>
                    <measurement group_id="O2" value="7.80" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outpatient Follow-up Compliance</title>
        <description>Scoring System: 0= not compliant, 1=compliant</description>
        <time_frame>1 Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Outpatient Follow-up Compliance</title>
          <description>Scoring System: 0= not compliant, 1=compliant</description>
          <units>units on follow up compliance scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread=".14"/>
                    <measurement group_id="O2" value=".70" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inpatient Treatment Alliance Scale (ITAS)</title>
        <description>The I-TAS is a 10-item, Likert-style rating scale designed to assess a patient's composite treatment alliance as it develops across multi-disciplinary treatment components. The I-TAS was intended to measure the primary alliance factors identified by Hatcher and Barends (1996) of bond, goals and collaboration. Each question is scored on a scale of 0 (Completely False) to 6 (Completely True). Total scores on the ITAS range from 0 to 60, with higher scores representing greater alliance with the treatment team (better outcome). The reported score is an average of each participant's total score on the ITAS.</description>
        <time_frame>7 days post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
          </group>
        </group_list>
        <measure>
          <title>Inpatient Treatment Alliance Scale (ITAS)</title>
          <description>The I-TAS is a 10-item, Likert-style rating scale designed to assess a patient's composite treatment alliance as it develops across multi-disciplinary treatment components. The I-TAS was intended to measure the primary alliance factors identified by Hatcher and Barends (1996) of bond, goals and collaboration. Each question is scored on a scale of 0 (Completely False) to 6 (Completely True). Total scores on the ITAS range from 0 to 60, with higher scores representing greater alliance with the treatment team (better outcome). The reported score is an average of each participant's total score on the ITAS.</description>
          <units>Scored units on ITAS Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.52" spread="3.69"/>
                    <measurement group_id="O2" value="53.15" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>IV Ketamine .25mg/kg
Ketamine: IV of Ketamine (.25mg/kg)</description>
        </group>
        <group group_id="E2">
          <title>Diphenhydramine</title>
          <description>25mg Diphenhydramine
Diphenhydramine: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis and Suicidality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Perceptual Disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toe Numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GI Distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Systolic BP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Ross, MD/ Principal Investigator</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212 562 4097</phone>
      <email>Stephen.Ross@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

